SUMMIT (dpa-AFX) - Shares of Celgene (CELG) continue to see significant weakness in late-day trading on Friday after an early sell-off. After hitting its lowest intraday level in four months, Celgene is currently down by 10.7 percent.
Celgene initially came under pressure after the biopharmaceutical company discontinued two studies of its drug to treat Crohn's disease and said it would not begin a third.
Copyright RTT News/dpa-AFX